Asset
PEGIPANERMIN
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03943264 | phase1 | completed | 2019-11-20 | 2021-06-30 | Inmune Bio, Inc. | A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's |
| NCT05318976 | phase2 | completed | 2022-02-28 | 2025-05-12 | Inmune Bio, Inc. | A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation |
| NCT05522387 | phase2 | terminated | 2023-02-21 | 2024-06-05 | Inmune Bio, Inc. | An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease |
| NCT04370236 | phase2_3 | terminated | 2020-10-21 | 2021-10-13 | Inmune Bio, Inc. | INB03 for the Treatment of Pulmonary Complications From COVID-19 |
| NCT05321498 | phase2 | withdrawn | 2023-06-01 | 2023-10-26 | Inmune Bio, Inc. | Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation |
FDA applications (0)
This company has no applications containing this asset.